Kawasumi Laboratories Inc. announced consolidated earnings results for the year ended March 31, 2016. For the year, the company reported net sales of ¥28,135 million against ¥28,408 million a year ago. Operating income was ¥2,130 million against ¥1,406 million a year ago. Ordinary income was ¥2,177 million against ¥1,835 million a year ago. Profit attributable to owners of parent was ¥1,599 million or ¥70.54 per share against ¥975 million or ¥42.66 per share a year ago. Cash flows from operating activities were ¥3,225 million against ¥5,059 million a year ago. Profit before income taxes was ¥2,160 million against ¥1,749 million a year ago. Purchase of property, plant and equipment was ¥656 million against ¥288 million a year ago. Purchase of intangible assets was ¥69 million against ¥45 million a year ago.

The company declared year-end dividend of ¥7.50 per share for the year ended March 31, 2016. The dividend payable on June 24, 2016.

The company provided dividend guidance for the year ending March 31, 2017. For the period, the company expects dividend of ¥7.50 per share.

The company provided consolidated earnings guidance for the six months ending September 30, 2016 and full year ending March 31, 2017. For the six months, the company expects net sales of ¥12,700 million, operating income of ¥300 million, ordinary income of ¥300 million and profit attributable to owners of parent of ¥200 million or ¥9.17 per share.

For the full year ending March 31, 2017, the company expects net sales of ¥26,000 million, operating income of ¥1,000 million, ordinary income of ¥1,000 million and profit attributable to owners of parent of ¥700 million or ¥32.09 per share.